Amol Akhade, Senior Medical and Hemato-Oncologist based in Mumbai, India, shared a post on LinkedIn:
“And then There were TWO.
Nice summary slide to Compare Sacituzumab govitecan-hziy and Sacituzumab tirumotecan in advanced TNBC based upon recently published data of Later in Nature.
Do note The difference in structure and efficacy of both ADCs.
More posts featuring mTNBC.